Impact of Disease History on the Efficacy of Ritlecitinib in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

    September 2026 in “ JID Innovations ”
    Brett King, Wilma Bergfeld, Paweł Brzewski … Ernest H. Law
    Studysummary This study found that in alopecia areata patients, starting ritlecitinib treatment within one year of an episode led to better hair regrowth outcomes compared to starting after a year.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jidinnovations.org →
    Discuss this study in the Community →

    Research cited in this study 17

    1. Identification of Stigmatization and Relevant Predictors in People with Alopecia Areata and Androgenetic Alopecia: A Comparative Cross-Sectional Study in German-Speaking Countries and the USA Acta Dermato Venereologica · 2025
    2. Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme Journal of the European Academy of Dermatology and Venereology · 2025
    3. Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-Centre Real-World Retrospective Study Acta dermato-venereologica · 2023
    4. Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2 Dermatology and Therapy · 2023
    5. Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study Dermatology and therapy · 2023
    6. Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials British Journal of Dermatology · 2023
    7. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    8. Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2021
    9. The Epidemiology of Alopecia Areata: A Population-Based Cohort Study in UK Primary Care British Journal of Dermatology · 2021
    10. A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States Clinical Cosmetic and Investigational Dermatology · 2020
    11. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    12. Health-Related Quality of Life Among Patients With Alopecia Areata: A Systematic Review Journal of The American Academy of Dermatology · 2016
    13. Alopecia Areata and Health-Related Quality of Life: A Systematic Review and Meta-Analysis British Journal of Dermatology · 2016
    14. The Autoimmune Basis of Alopecia Areata: A Comprehensive Review Autoimmunity reviews · 2014
    15. Early Intervention with High-Dose Steroid Pulse Therapy Prolongs Disease-Free Interval of Severe Alopecia Areata: A Retrospective Study Annals of Dermatology · 2013
    16. Prognostic Factors in Methylprednisolone Pulse Therapy for Alopecia Areata Journal of dermatology · 2011
    17. Intralesional Steroids for Alopecia Areata International Journal of Trichology · 2010